Mylan announced it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) of Eszopiclone Tablets, the generic version of Sunovion’s Lunesta.

Lunesta is a non-benzodiazepine pyrrolopyrazine hypnotic indicated for the treatment of insomnia (decreased sleep latency and improved sleep maintenance). Its effect is believed to result from its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.

RELATED: Psychiatric Disorders Resource Center

Eszopiclone Tablets are available in 1mg, 2mg, and 3mg strength tablets.

For more information call (800) RX-MYLAN or visit